🇪🇺 Beta-D-N4-Hydroxycytidine in European Union

Beta-D-N4-Hydroxycytidine (MOLNUPIRAVIR) regulatory status in European Union.

Marketing authorisation

EMA

  • Application: EMEA/H/C/005789
  • Local brand name: Lagevrio
  • Status: application withdrawn

Beta-D-N4-Hydroxycytidine in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Metabolic approved in European Union

Frequently asked questions

Is Beta-D-N4-Hydroxycytidine approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for Beta-D-N4-Hydroxycytidine in European Union?

Msd K.K. is the originator. The local marketing authorisation holder may differ — check the official source linked above.